Difference between revisions of "Team:BostonU/Experiments"

 
(3 intermediate revisions by one other user not shown)
Line 216: Line 216:
 
</div></div>
 
</div></div>
 
<div id="panel1" class="link-slideup">
 
<div id="panel1" class="link-slideup">
 +
  <p class="inline-heading-type mainwrap">Characterizing Our Cell Free System</p>
 
   <p class="body-type mainwrap">
 
   <p class="body-type mainwrap">
In order to characterize the fluorescence capabilities of our cell-free system, we measured the fluorescence from a plasmid coding for a  constitutively active deGFP at varying concentrations. Specifically, the plasmid was at added to cell-free at 0 nM, 10 nM, 20 nM, 30 nM, and 40 nM concentrations. Fluorescence was measured over eight hours. The data was then used to inform our <a href="https://2017.igem.org/Team:BostonU/Model">model</a>.</p>
+
In order to characterize the fluorescence capabilities of our cell-free system, we measured the fluorescence from a plasmid coding for a  constitutively active deGFP at varying concentrations. Our plasmid of choice was pBEST, which comes from the Noireaux Lab, whose cell-free protocol we used to make our in house cell-free. pBEST was shown by the Noireaux lab to have high performance in cell-free [1]. The plasmid was designed modularly, so each part could be replaced using a simple digestion ligation reaction. </p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
+
   <p class="body-type mainwrap">
   <p class="body-type mainwrap"> Our source plasmid pBEST comes from the Noireaux Lab, whose cell-free protocol we used to make our in house cell-free. pBEST was shown by the Noireaux lab to have high performance in cell-free [1]. The plasmid was designed modularly, so each part could be replaced using a simple digestion ligation reaction. </p>
+
The plasmid was added to cell-free at 0 nM, 10 nM, 20 nM, 30 nM, and 40 nM concentrations. Fluorescence was measured over eight hours. The data was then used to inform our <a href="https://2017.igem.org/Team:BostonU/Model">model</a>.</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 +
 +
  <p class="inline-heading-type mainwrap">Characterizing Toehold Activity Our Cell Free System</p>
 +
 
<p class="body-type mainwrap">We began by adapting our source plasmid to contain a toehold as its RBS. We did this by using primers: one set of master primers, which add in XbaI sites used to clone our final product into our final plasmid. The other set of primers added in the toehold or trigger architecture. The toehold switch and trigger sequences came from the best performing forward engineered toehold switch designed by Green et al [2]. We combined the two PCR products into a single linear piece of DNA using overlap extension PCR. </p>
 
<p class="body-type mainwrap">We began by adapting our source plasmid to contain a toehold as its RBS. We did this by using primers: one set of master primers, which add in XbaI sites used to clone our final product into our final plasmid. The other set of primers added in the toehold or trigger architecture. The toehold switch and trigger sequences came from the best performing forward engineered toehold switch designed by Green et al [2]. We combined the two PCR products into a single linear piece of DNA using overlap extension PCR. </p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
  
<p class="body-type mainwrap"><img src="https://static.igem.org/mediawiki/2017/a/ab/T--BostonU--Experiments1.png" height="300" style="float:right;"></img>After this step, our plan was to test these linear PCR products in the cell-free transcription translation system. However, we observed basal levels of expression from linearized deGFP compared to the plasmid deGFP. After performing a literature search, we hypothesized that either our linear fragments were being degraded by exonucleases present in our cell-free system or RNAse present in our cell-free system degrading our RNA. In order to prevent exonuclease activity, we added purified gamS protein to our cell-free, which inhibits exonuclease activity. We also added commercial RNase inhibitor. However, after running cell-free tests with gamS, RNAse inhibitor, and linear DNA, we still saw only basal levels of expression. From this point onward we tested all our constructs in cell-free as plasmids. </p>
+
<p class="body-type mainwrap"><img src="https://static.igem.org/mediawiki/2017/a/ab/T--BostonU--Experiments1.png" height="300" style="float:right;"></img>After this step, our plan was to test these linear PCR products in the cell-free transcription translation system. We wanted to test linear fragments beacuse it would drastically cut down on time and cost, and thus improve throughput. However, we observed basal levels of expression from linearized deGFP compared to the plasmid deGFP. After performing a literature search, we hypothesized that either our linear fragments were being degraded by exonucleases present in our cell-free system or RNAse present in our cell-free system degrading our RNA. In order to prevent exonuclease activity, we added purified gamS protein to our cell-free, which inhibits exonuclease activity. We also added commercial RNase inhibitor. However, after running cell-free tests with gamS, RNAse inhibitor, and linear DNA, we still saw only basal levels of expression. From this point onward we tested all our constructs in cell-free as plasmids. </p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">We moved on to adding our triggers as plasmid DNA. This resulted in expression higher than basal levels, however fluorescence still failed to reach the level of the constitutively active deGFP gene and was actually quite low.<img src="https://static.igem.org/mediawiki/2017/3/37/T--BostonU--Experiments3.png" height="300" style="float:left;">We hypothesized that too much of the cell-free's transcriptional machinery was being allocated to transcribing the trigger DNA and not enough was being allocated towards transcribing the toehold. We then decided to add the trigger as RNA instead as DNA. <img src="https://static.igem.org/mediawiki/2017/0/0b/T--BostonU--Experiments2.png" height="300" style="float:right;">We transcribed our trigger DNA into RNA using the Ampliscribe T7 Flash Transcription Kit before adding it into the cell-free system. Adding our trigger as RNA showed a more significant increase in fluorescence. Results from this experiment can be seen on the <a href="#">results</a> page.</p>
 
<p class="body-type mainwrap">We moved on to adding our triggers as plasmid DNA. This resulted in expression higher than basal levels, however fluorescence still failed to reach the level of the constitutively active deGFP gene and was actually quite low.<img src="https://static.igem.org/mediawiki/2017/3/37/T--BostonU--Experiments3.png" height="300" style="float:left;">We hypothesized that too much of the cell-free's transcriptional machinery was being allocated to transcribing the trigger DNA and not enough was being allocated towards transcribing the toehold. We then decided to add the trigger as RNA instead as DNA. <img src="https://static.igem.org/mediawiki/2017/0/0b/T--BostonU--Experiments2.png" height="300" style="float:right;">We transcribed our trigger DNA into RNA using the Ampliscribe T7 Flash Transcription Kit before adding it into the cell-free system. Adding our trigger as RNA showed a more significant increase in fluorescence. Results from this experiment can be seen on the <a href="#">results</a> page.</p>
Line 238: Line 242:
 
<p class="body-type mainwrap">Once toeholds were showing positive results in cell-free, our next goal was to characterize recombinase activity in cell-free. </p>
 
<p class="body-type mainwrap">Once toeholds were showing positive results in cell-free, our next goal was to characterize recombinase activity in cell-free. </p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 +
 +
  <p class="inline-heading-type mainwrap">Characterizing Recombinase Activity in Our Cell Free System</p>
  
 
<p class="body-type mainwrap"></img>In order to determine how recombinases function in cell-free, we obtained a commercially available Cre recombinase protein from New England Biolabs. We designed a reporter plasmid with the same design as pBEST, but with a premature terminator before the deGFP gene.<img src="https://static.igem.org/mediawiki/2017/e/e4/T--BostonU--CreRecombFig1.svg" height="300" style="float:right;"> This terminator was flanked with recombinase recognition sites, and in the presence of Cre should be excised, allowing for deGFP expression. The figure below shows the reporter architecture.</p>
 
<p class="body-type mainwrap"></img>In order to determine how recombinases function in cell-free, we obtained a commercially available Cre recombinase protein from New England Biolabs. We designed a reporter plasmid with the same design as pBEST, but with a premature terminator before the deGFP gene.<img src="https://static.igem.org/mediawiki/2017/e/e4/T--BostonU--CreRecombFig1.svg" height="300" style="float:right;"> This terminator was flanked with recombinase recognition sites, and in the presence of Cre should be excised, allowing for deGFP expression. The figure below shows the reporter architecture.</p>
Line 257: Line 263:
  
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 +
 +
  <p class="inline-heading-type mainwrap">Additional Experiments and Future Directions</p>
  
 
<p class="body-type mainwrap">A large amount of time during our project was devoted to developing a more modular version of the pBEST plasmid in order to allow for easy exchange of toehold sequences and genes and the addition of fluorescent fusion proteins. We wanted to tag our recombinases with fluorescent proteins so that we could monitor their level of expression in our cell-free system. Though we were not able to complete this, here we provide a detailed methodology of our plans and what could be accomplished in the future: </p>
 
<p class="body-type mainwrap">A large amount of time during our project was devoted to developing a more modular version of the pBEST plasmid in order to allow for easy exchange of toehold sequences and genes and the addition of fluorescent fusion proteins. We wanted to tag our recombinases with fluorescent proteins so that we could monitor their level of expression in our cell-free system. Though we were not able to complete this, here we provide a detailed methodology of our plans and what could be accomplished in the future: </p>

Latest revision as of 23:12, 1 November 2017

EXPERIMENTS